H.C. Wainwright reiterates Buy on BridgeBio stock on trial data

BridgeBio (BBIO) reiterated strong momentum: Phase 3 ATTRibute-CM analyses showed clinically meaningful improvement in left ventricular systolic function in 54% of acoramidis patients vs 20% on placebo at Month 30, and 53% vs placebo at Month 42 (conservative: 34% vs 9% at Month 30). The stock at $76.57 received renewed Wall Street confidence with H.C. Wainwright restating a Buy and $120 target after 2Q26 revenue of $243.7M vs $221M consensus, including U.S. Attruby net product revenue of $222.4M. Canaccord raised its price target to $106 (Buy) and Mizuho to $110 as peak sales estimates for U.S. Attruby increased to ~$4B.

Analysis

BBIO’s investable story is shifting from “interesting orphan drug” to “can this become a durable franchise?” The market should care more about the launch curve than the imaging substudy: >$200M quarterly net product revenue with very high gross margin implies operating leverage can compound fast if new-patient starts keep accelerating. The second-order winner is the specialty distribution / payer infrastructure around ATTR-CM; the real loser is not just the incumbent stabilizer franchise, but any future entrant that needs to dislodge a product already winning first-line starts.

The near-term setup is less clean than the headline suggests because a 5M-share secondary creates technical supply at exactly the moment consensus is getting more bullish. That overhang can cap multiple expansion for 1-3 weeks even if fundamentals are intact, especially if the stock has already repriced on repeated target raises. The bigger medium-term question is whether diagnosis growth and payer access can sustain the current pace; if not, peak-sales math gets pulled forward too aggressively and the stock could de-rate quickly.

Contrarian view: the market may be underestimating how much of the current optimism is based on early, easier-to-capture patients rather than a fully penetrated addressable pool. The open-label/completer data support narrative, but they do not eliminate the risk that adoption slows once the most obvious patients are harvested or step edits tighten. Falsifiers: a quarterly Attruby run-rate slipping below roughly $200M, weaker new-start commentary, or any evidence the secondary is being sold aggressively into the market.

Key Decisions for Investors

• BBIO: wait for post-secondary weakness before adding; initiate a starter long on a pullback toward the low-70s, targeting $95-$100 over 3-6 months. Risk/reward is attractive only if new-start momentum is reaffirmed; cut if the stock closes below ~$68 or if next-quarter revenue misses the current run-rate.
• BBIO / XBI pair: long BBIO, short XBI to isolate commercial execution from broader biotech beta. This is a cleaner expression than a naked long if the market wants to fade small-cap biotech multiples; reassess if XBI leadership broadens or BBIO loses relative strength after the offering.
• PFE relative-value watch: consider a small short PFE vs long BBIO basket only if payer/access data confirm continued first-line share gains. The thesis is that the incumbent’s TTR economics are more vulnerable to share erosion than the market is pricing, but this needs follow-through data before sizing.
• If already long BBIO, use the secondary-induced strength/vol spike to overwrite a portion with short-dated calls. This monetizes the overhang while leaving upside open if the market confirms that launch velocity is still accelerating.